187 related articles for article (PubMed ID: 22935933)
1. Effective use of a clinical decision-support system to advance antimicrobial stewardship.
Patel J; Esterly JS; Scheetz MH; Bolon MK; Postelnick MJ
Am J Health Syst Pharm; 2012 Sep; 69(18):1543-4. PubMed ID: 22935933
[No Abstract] [Full Text] [Related]
2. The unexpected benefits of the national piperacillin/tazobactam shortage on antibiotic stewardship.
Cunha BA
Infect Dis (Lond); 2016 Apr; 48(4):328-329. PubMed ID: 26592309
[No Abstract] [Full Text] [Related]
3. Rationale and evidence for extended infusion of piperacillin-tazobactam.
Kaufman SE; Donnell RW; Hickey WS
Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin-Tazobactam Usage at a Tertiary Pediatric Hospital: An Antimicrobial Stewardship Review.
Janowski AB; Michaels MG; Martin JM; Green MD
J Pediatric Infect Dis Soc; 2016 Sep; 5(3):342-5. PubMed ID: 26407269
[TBL] [Abstract][Full Text] [Related]
5. Role of newer broad-spectrum beta-lactam and fluoroquinolone antibiotics in children.
Bonafede ME; Blumer JL
Adv Pediatr Infect Dis; 1996; 12():71-108. PubMed ID: 9033976
[No Abstract] [Full Text] [Related]
6. Patient and physician predictors of patient receipt of therapies recommended by a computerized decision support system when initially prescribed broad-spectrum antibiotics: a cohort study.
Chow AL; Lye DC; Arah OA
J Am Med Inform Assoc; 2016 Apr; 23(e1):e58-70. PubMed ID: 26342216
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
Patel GW; Patel N; Lat A; Trombley K; Enbawe S; Manor K; Smith R; Lodise TP
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):236-40. PubMed ID: 19500529
[TBL] [Abstract][Full Text] [Related]
8. Knowledge, attitudes, and behaviors regarding piperacillin-tazobactam prescribing practices: results from a multicenter study.
Antoine TL; Curtis AB; Blumberg HM; Desilva K; Fransua M; Gould CV; King M; Kraman AA; Pack J; Ribner B; Seybold U; Steinberg JP; Wells JB; Sinkowitz-Cochran RL; Cardo D; Jernigan JA; Gaynes RP
Infect Control Hosp Epidemiol; 2006 Nov; 27(11):1274-7. PubMed ID: 17080393
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin-Tazobactam-induced Adverse Drug Events in Pediatric Patients on Outpatient Parenteral Antimicrobial Therapy.
Yusef D; Gonzalez BE; Foster CB; Goldfarb J; Saracusa C; Worley S; Sabella C
Pediatr Infect Dis J; 2017 Jan; 36(1):50-52. PubMed ID: 27749652
[TBL] [Abstract][Full Text] [Related]
11. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
Attivi D; Gibaud S
Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
[TBL] [Abstract][Full Text] [Related]
12. Effect of adding piperacillin-tazobactam to automated dispensing cabinets on promptness of first-dose antibiotics in hospitalized patients.
Lo A; Zhu JN; Richman M; Joo J; Chan P
Am J Health Syst Pharm; 2014 Oct; 71(19):1663-7. PubMed ID: 25225451
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
Lee GC; Liou H; Yee R; Quan CF; Neldner K
Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis.
Pathengay A; Mathai A; Shah GY; Ambatipudi S
J Cataract Refract Surg; 2010 Dec; 36(12):2210-1. PubMed ID: 21111328
[No Abstract] [Full Text] [Related]
15. Lack of significant variability among different methods for calculating antimicrobial days of therapy.
Kubin CJ; Jia H; Alba LR; Yoko Furuya E
Infect Control Hosp Epidemiol; 2012 Apr; 33(4):421-3. PubMed ID: 22418642
[TBL] [Abstract][Full Text] [Related]
16. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Grau S; Lozano V; Valladares A; Cavanillas R; Xie Y; Nocea G
Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination].
Leclerc T; Perez JP; Debien B; Clapson P; Lenoir B
Ann Fr Anesth Reanim; 2007 Dec; 26(12):1056-8. PubMed ID: 17961967
[TBL] [Abstract][Full Text] [Related]
18. Comparative assessment of antimicrobial usage measures in the Department of Veterans Affairs.
Schirmer PL; Mercier RC; Ryono RA; Nguyen N; Lucero CA; Oda G; Holodniy M
Infect Control Hosp Epidemiol; 2012 Apr; 33(4):409-11. PubMed ID: 22418639
[TBL] [Abstract][Full Text] [Related]
19. Importance of infusion volume and pump characteristics in extended administration of ß-lactam antibiotics.
Claus B; Buyle F; Robays H; Vogelaers D
Antimicrob Agents Chemother; 2010 Nov; 54(11):4950. PubMed ID: 20823285
[No Abstract] [Full Text] [Related]
20. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
Youssif E; Aseeri M; Khoshhal S
J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
